Seres Therapeutics (STU:1S90) Research & Development: €40.08 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1S90 Seres Therapeutics Inc STU:1S90
25 GF Score
Price €4.05
! 5 Warning Signs
View Full Analysis

What is Seres Therapeutics Research & Development?

Seres Therapeutics STU:1S90 -4.71% 25 Research & Development is €40.08 Mil as of Jun. 2026. GuruFocus rates STU:1S90 with a GF Score™ of 25/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Seres Therapeutics's Research & Development for the three months ended in Jun. 2026 was €7.93 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was €40.08 Mil.

Seres Therapeutics  (STU:1S90) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Seres Therapeutics Research & Development Related Terms

Seres Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Seres Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seres Therapeutics Research & Development Chart

Seres Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 125.57 103.51 107.84 61.69 41.90

Seres Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.22 10.75 9.98 11.41 7.93
STU:1S90
25GF Score
Seres Therapeutics Inc STU:1S90
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seres Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €40.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €40.08 Mil mean?
Seres Therapeutics (STU:1S90) has a Research & Development of €40.08 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Seres Therapeutics and its competitors.
Is Seres Therapeutics' Research & Development too high?
Seres Therapeutics' current Research & Development is €40.08 Mil. Overall, Seres Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Seres Therapeutics' Research & Development compare to IBO and TIL?
Seres Therapeutics' Research & Development of €40.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Seres Therapeutics and its competitors. Seres Therapeutics's current Research & Development is €40.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seres Therapeutics stock overvalued right now?
Seres Therapeutics (STU:1S90) has a current Research & Development of €40.08 Mil. The current Research & Development is €40.08 Mil. Seres Therapeutics' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Seres Therapeutics (STU:1S90), the current Research & Development is €40.08 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seres Therapeutics Business Description

Other Exchanges MCRB:USA
Address 101 Cambridgepark Drive, Cambridge, MA, USA, 02140
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
25GF Score

Get the complete analysis for STU:1S90

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.05
Price